PMID- 11526479
OWN - NLM
STAT- MEDLINE
DCOM- 20010913
LR  - 20141120
IS  - 0950-9232 (Print)
IS  - 0950-9232 (Linking)
VI  - 20
IP  - 36
DP  - 2001 Aug 16
TI  - IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to 
      mesenchyme transition.
PG  - 4942-50
AB  - The epithelium to mesenchyme transition is thought to play a fundamental role 
      during embryonic development and tumor progression. Loss of cell-cell adhesion 
      and modification of both cell morphology and gene expression are the main events 
      associated with this transition. There is a large amount of evidence suggesting 
      that growth factors can initiate these events. Yet, the connection from growth 
      factor induction to changes in cell adhesion and morphology is largely unknown. 
      To elucidate this connection, we have investigated the action of IGF-II on 
      E-cadherin/beta-catenin complex-mediated cell-cell adhesion and on 
      beta-catenin/TCF-3 mediated gene expression. We can show that (1) IGF-II induces 
      a rapid epithelium to mesenchymal transition; (2) IGF1R, the receptor for IGF-II, 
      belongs to the same membrane complex as E-cadherin and beta-catenin; (3) IGF-II 
      induces a redistribution of beta-catenin from the plasma membrane to the nucleus 
      and an intracellular sequestration and degradation of E-cadherin; (4) IGF-II 
      induces the transcription of beta-catenin/TCF-3 target genes. Based on the given 
      case of IGF-II and E-cadherin/beta-catenin complex, this study reveals the 
      backbone of a cascade connecting growth factor signaling with cell-cell adhesion 
      during EMT.
FAU - Morali, O G
AU  - Morali OG
AD  - Developmental Genetics of Melanocytes, UMR 146 CNRS-Institut Curie, Bat. 110, 
      91405, Orsay Cedex, France.
FAU - Delmas, V
AU  - Delmas V
FAU - Moore, R
AU  - Moore R
FAU - Jeanney, C
AU  - Jeanney C
FAU - Thiery, J P
AU  - Thiery JP
FAU - Larue, L
AU  - Larue L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Oncogene
JT  - Oncogene
JID - 8711562
RN  - 0 (CTNNB1 protein, mouse)
RN  - 0 (Cadherins)
RN  - 0 (Ctnnb1 protein, rat)
RN  - 0 (Cytoskeletal Proteins)
RN  - 0 (Macromolecular Substances)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (RNA, Messenger)
RN  - 0 (Trans-Activators)
RN  - 0 (beta Catenin)
RN  - 136601-57-5 (Cyclin D1)
RN  - 67763-97-7 (Insulin-Like Growth Factor II)
RN  - EC 2.7.10.1 (Receptor, IGF Type 1)
SB  - IM
MH  - 3T3 Cells
MH  - Active Transport, Cell Nucleus
MH  - Animals
MH  - Cadherins/metabolism
MH  - Cell Membrane/metabolism
MH  - Cell Nucleus/metabolism
MH  - Cyclin D1/biosynthesis/genetics
MH  - Cytoskeletal Proteins/*metabolism
MH  - Epithelium/*embryology
MH  - Insulin-Like Growth Factor II/*pharmacology
MH  - Macromolecular Substances
MH  - Mesoderm/*cytology
MH  - Mice
MH  - Proto-Oncogene Proteins c-myc/biosynthesis/genetics
MH  - RNA, Messenger/biosynthesis
MH  - Rats
MH  - Receptor, IGF Type 1/metabolism
MH  - *Trans-Activators
MH  - Tumor Cells, Cultured
MH  - beta Catenin
EDAT- 2001/08/30 10:00
MHDA- 2001/09/14 10:01
CRDT- 2001/08/30 10:00
PHST- 2001/03/13 00:00 [received]
PHST- 2001/05/04 00:00 [revised]
PHST- 2001/05/23 00:00 [accepted]
PHST- 2001/08/30 10:00 [pubmed]
PHST- 2001/09/14 10:01 [medline]
PHST- 2001/08/30 10:00 [entrez]
AID - 10.1038/sj.onc.1204660 [doi]
PST - ppublish
SO  - Oncogene. 2001 Aug 16;20(36):4942-50. doi: 10.1038/sj.onc.1204660.